| Financial Information Relating to Reportable Segments |
Following is financial
information relating to the Company’s reportable segments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Quarter
Ended
December 31,
|
|
|
Six Months
Ended
December 31,
|
|
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
69,808 |
|
|
$ |
63,080 |
|
|
$ |
142,111 |
|
|
$ |
126,121 |
|
|
Hematology
|
|
|
4,854 |
|
|
|
4,628 |
|
|
|
10,147 |
|
|
|
9,532 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net
sales
|
|
$ |
74,662 |
|
|
$ |
67,708 |
|
|
$ |
152,258 |
|
|
$ |
135,653 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
37,878 |
|
|
$ |
37,953 |
|
|
$ |
77,862 |
|
|
$ |
76,413 |
|
|
Hematology
|
|
|
1,681 |
|
|
|
1,427 |
|
|
|
3,599 |
|
|
|
3,349 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before
income taxes
|
|
|
39,559 |
|
|
|
39,380 |
|
|
|
81,461 |
|
|
|
79,762 |
|
|
Unallocated corporate
expenses and equity method investee losses
|
|
|
(1,686 |
) |
|
|
(1,707 |
) |
|
|
(3,088 |
) |
|
|
(3,136 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings
before income taxes
|
|
$ |
37,873 |
|
|
$ |
37,673 |
|
|
$ |
78,373 |
|
|
$ |
76,626 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|